Confluence Wealth Services Inc. Purchases 8,633 Shares of Zoetis Inc. $ZTS

Key Points

• Confluence Wealth Services Inc. boosted its stake in Zoetis by 553.8%, buying 8,633 shares to hold 10,192 shares worth about $1.282 million at quarter-end.
• Analyst coverage is mixed with a consensus rating of "Hold" (7 Buys, 7 Holds, 1 Sell) and an average price target of $152.25.
• Zoetis reported quarterly EPS of $1.48 and set FY2026 guidance at 7.00–7.10 EPS; it also declared a quarterly dividend of $0.53 per share (yield ~1.8%, ex-dividend Apr 20).

Confluence Wealth Services Inc. boosted its position in Zoetis Inc. (NYSE:ZTS - Free Report) by 553.8% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,192 shares of the company's stock after buying an additional 8,633 shares during the period. Confluence Wealth Services Inc.'s holdings in Zoetis were worth $1,282,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in ZTS. Halbert Hargrove Global Advisors LLC increased its position in Zoetis by 496.6% in the 3rd quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company's stock valued at $25,000 after buying an additional 144 shares in the last quarter. Global Wealth Strategies & Associates bought a new stake in Zoetis in the 4th quarter valued at about $25,000. Lodestone Wealth Management LLC bought a new stake in Zoetis in the 4th quarter valued at about $30,000. KERR FINANCIAL PLANNING Corp bought a new stake in Zoetis in the 3rd quarter valued at about $31,000. Finally, Holos Integrated Wealth LLC bought a new stake in Zoetis in the 4th quarter valued at about $32,000. 92.80% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages recently commented on ZTS. BTIG Research reaffirmed a "buy" rating and issued a $160.00 target price on shares of Zoetis in a research report on Thursday, February 26th. Wall Street Zen raised Zoetis from a "hold" rating to a "buy" rating in a research report on Saturday, February 21st. Weiss Ratings lowered Zoetis from a "hold (c-)" rating to a "sell (d+)" rating in a research report on Friday, March 27th. Piper Sandler reaffirmed a "neutral" rating and issued a $135.00 target price (down from $190.00) on shares of Zoetis in a research report on Thursday, January 22nd. Finally, Leerink Partners reaffirmed a "market perform" rating on shares of Zoetis in a research report on Tuesday, March 10th. Seven research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $152.25.

Zoetis Price Performance

ZTS stock opened at $116.01 on Friday. The company has a market capitalization of $48.80 billion, a P/E ratio of 19.27, a price-to-earnings-growth ratio of 1.79 and a beta of 0.98. The company has a debt-to-equity ratio of 2.71, a quick ratio of 1.94 and a current ratio of 3.03. Zoetis Inc. has a 52-week low of $113.29 and a 52-week high of $172.23. The business has a 50-day simple moving average of $121.02 and a two-hundred day simple moving average of $125.73.

Zoetis (NYSE:ZTS - Get Free Report) last released its quarterly earnings results on Thursday, February 12th. The company reported $1.48 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.40 by $0.08. The business had revenue of $2.39 billion during the quarter, compared to the consensus estimate of $2.36 billion. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The company's quarterly revenue was up 3.0% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.40 EPS. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. Research analysts expect that Zoetis Inc. will post 7.02 EPS for the current fiscal year.

Zoetis Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 2nd. Shareholders of record on Monday, April 20th will be paid a dividend of $0.53 per share. The ex-dividend date is Monday, April 20th. This represents a $2.12 dividend on an annualized basis and a yield of 1.8%. Zoetis's payout ratio is 35.22%.

Zoetis Company Profile

Zoetis Inc NYSE: ZTS is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company's offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.